- Home
- VMEO vs LXRX Comparison
VMEO vs LXRX Comparison
Compare VMEO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- LXRX
- Stock Information
- Founded
- VMEO 2004
- LXRX 1995
- Country
- VMEO United States
- LXRX United States
- Employees
- VMEO N/A
- LXRX N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- LXRX Health Care
- Exchange
- VMEO Nasdaq
- LXRX Nasdaq
- Market Cap
- VMEO 652.9M
- LXRX 552.4M
- IPO Year
- VMEO N/A
- LXRX 2000
- Fundamental
- Price
- VMEO $7.83
- LXRX $1.25
- Analyst Decision
- VMEO Hold
- LXRX Buy
- Analyst Count
- VMEO 4
- LXRX 5
- Target Price
- VMEO $6.81
- LXRX $3.23
- AVG Volume (30 Days)
- VMEO 1.5M
- LXRX 2.0M
- Earning Date
- VMEO 10-28-2025
- LXRX 11-06-2025
- Dividend Yield
- VMEO N/A
- LXRX N/A
- EPS Growth
- VMEO N/A
- LXRX N/A
- EPS
- VMEO 0.00
- LXRX N/A
- Revenue
- VMEO $416,596,000.00
- LXRX $70,864,000.00
- Revenue This Year
- VMEO $2.98
- LXRX $66.55
- Revenue Next Year
- VMEO $4.96
- LXRX N/A
- P/E Ratio
- VMEO $2,378.13
- LXRX N/A
- Revenue Growth
- VMEO N/A
- LXRX 1255.21
- 52 Week Low
- VMEO $3.64
- LXRX $0.28
- 52 Week High
- VMEO $7.90
- LXRX $1.66
- Technical
- Relative Strength Index (RSI)
- VMEO 79.39
- LXRX 40.69
- Support Level
- VMEO $7.76
- LXRX $1.31
- Resistance Level
- VMEO $7.82
- LXRX $1.53
- Average True Range (ATR)
- VMEO 0.03
- LXRX 0.08
- MACD
- VMEO -0.06
- LXRX -0.02
- Stochastic Oscillator
- VMEO 90.00
- LXRX 18.57
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.